Idecabtagene vicleucel
Idecabtagene vicleucel (pronounced as i-dek-ab-TAG-e-ne vik-LOO-sel) is a type of immunotherapy used in the treatment of multiple myeloma, a type of cancer that forms in a type of white blood cell called a plasma cell.
Etymology
The name "Idecabtagene vicleucel" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature. The "ide-" prefix refers to the immune effector function, "cabta-" refers to the target antigen, and "-gene vicleucel" refers to the genetic modification of the T cells.
Usage
Idecabtagene vicleucel is used for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Mechanism of Action
Idecabtagene vicleucel is a chimeric antigen receptor (CAR) T cell therapy. It works by modifying the patient's T cells to express a CAR that targets the B cell maturation antigen (BCMA), a protein that is nearly universally expressed on cancer cells in multiple myeloma.
Related Terms
- Immunotherapy
- Cancer
- Multiple Myeloma
- Immunomodulatory agent
- Proteasome inhibitor
- Chimeric antigen receptor
- B cell maturation antigen
External links
- Medical encyclopedia article on Idecabtagene vicleucel
- Wikipedia's article - Idecabtagene vicleucel
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski